Centene Posts $3.37 Adjusted EPS, Beats by $0.50 as Medical Costs Improve
Centene Corporation (NYSE: CNC) delivered a blockbuster first quarter that exceeded management's own expectations by approximately $0.50 per share, reporting adjusted earnings of $3.37 versus GAAP earnings of $3.11. The managed care giant's outperformance was driven by tangible progress in managing medical costs across its core Medicaid business, prompting management to raise full-year adjusted earnings guidance to greater than $3.40 per share.
Key Numbers
The numbers tell a story of operational improvement across multiple fronts. Total revenue reached $49.9 billion in Q1 2026, with premium and service revenues of $44.7 billion representing 5% year-over-year growth despite membership headwinds. The company's consolidated health benefits ratio (HBR) improved to 87.3% from 87.5% in the prior year period, with particularly strong performance in the core Medicaid segment.
Medicaid, representing 53% of premium revenues, posted an HBR of 93.1%, reflecting a 50 basis point improvement year-over-year. This improvement came despite ongoing membership attrition from Medicaid redeterminations, with total Medicaid enrollment declining to 12.4 million from 13.0 million a year ago. The Medicare segment delivered an impressive 84.9% HBR, benefiting from outperformance in both Medicare Advantage and the prescription drug plan (PDP) business.
The commercial marketplace business, while smaller following strategic exits, maintained profitability with a 75.3% HBR. Management noted this was slightly above expectations due to higher acuity among Silver Tier members, though pre-tax earnings remained in line with targets thanks to favorable administrative costs.
Operating efficiency gains were evident in the SG&A expense ratio, which improved to 7.6% from 7.9% a year ago. The company generated robust cash flow from operations of $4.4 billion, enabling $1.0 billion in debt reduction during the quarter through the repurchase of senior notes due 2027.
What Management Said
CEO Sarah London struck a confident tone, emphasizing the company's "tangible progress" in margin recovery efforts while strengthening fundamental operations across each business segment. Her commentary suggests the first quarter performance validates Centene's multi-year turnaround strategy initiated following the pandemic-era challenges.
Management attributed the Medicaid outperformance to three key factors: successful rate negotiations with states, continued progress in medical management initiatives, and moderate flu costs compared to historical trends. The company specifically highlighted that state-directed payments and rate increases adequately addressed medical cost trends, a critical factor given ongoing industry concerns about Medicaid margin pressure.
On the Medicare front, executives expressed satisfaction with the progression toward profitability in Medicare Advantage, noting the business no longer required a premium deficiency reserve in 2026 compared to the prior year. The massive PDP business, with 8.8 million members, continues to be a bright spot, operating at meaningfully lower SG&A ratios while delivering strong margins.
Regarding the commercial marketplace, management acknowledged the strategic downsizing from 5.6 million to 3.6 million members year-over-year but emphasized that first-quarter pre-tax earnings met expectations despite slightly elevated medical costs. The company expects future benefits from risk adjustment mechanisms to help offset current acuity challenges.
What to Watch
Several key dynamics warrant monitoring as 2026 unfolds. First, the updated guidance implies significant earnings acceleration through the remainder of the year, with full-year adjusted EPS now expected above $3.40 compared to the $3.37 already delivered in Q1. This suggests management sees continued margin expansion opportunities despite the strong start.
The Medicaid redetermination cycle remains a wildcard. While membership has stabilized somewhat, the company must continue demonstrating it can grow earnings despite the enrollment headwinds through margin improvement and rate adequacy. The 93.1% HBR in Q1 provides encouragement, but sustaining this level through varying seasonal patterns will be critical.
Medicare Advantage profitability represents another crucial proof point. The elimination of premium deficiency reserves signals improvement, but with industry-wide pressures from rising medical costs and regulatory changes, Centene must demonstrate sustainable margins in this business. The company's strategic shift toward dual-eligible special needs plans following CMS transitions adds complexity to year-over-year comparisons.
The commercial marketplace strategy bears watching as well. With membership down 40% year-over-year following strategic exits, Centene is clearly prioritizing margins over scale. The 75.3% HBR suggests this strategy is working, but the company must navigate ongoing acuity challenges while maximizing risk adjustment benefits.
Cash generation and capital deployment remain bright spots, with Q1's $4.4 billion in operating cash flow enabling meaningful debt reduction. The company's ability to sustain strong cash conversion while investing in operational improvements will determine its flexibility for future capital allocation priorities.
Looking ahead, Centene's raised guidance suggests management confidence in the durability of Q1 improvements. With the full-year HBR guided to 90.9%-91.7% and SG&A expected at 7.0%-7.6%, the company is targeting meaningful margin expansion from current levels. Success in achieving these targets while navigating industry headwinds would validate the multi-year turnaround effort and potentially drive further multiple expansion for this managed care leader.
*StockCliff Research*